Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy.
The Danish drugmaker said Monday that it’s dropping a lawsuit that claims Hims infringed on a key patent for its Wegovy products, and Hims agreed to no longer advertise compounded GLP-1 products. Novo is also allowing Hims to offer Wegovy injections and pills on its website at cash prices, as it does with other telehealth companies it has partnered with.
Hims said it will continue to offer compounded GLP-1s “if a provider determines that a compounded product is clinically necessary.” Novo said it reserves the right to refile its lawsuit in the future.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
